Patient P-01544
Therapy response
Improving
Tolerance
Stable
GI state
Stable
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
59%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S15
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 51 GI-04 recommended — GI Support Protocol GI-04
- Day 52 Patient accepted — Started GI-04 in the companion
- Day 58 ME-01 recommended — Monitoring Escalation ME-01
- Day 59 Patient accepted — Started ME-01 in the companion
- Day 60 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 66 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- Inflammatory activity+9
- Nutritional resilience-5
- Toxicity+4
- GI instability+3
- Treatment adherence-2
What helped?
- GI Support Protocol GI-04Day 51Result: symptom burden −32%
- Monitoring Escalation ME-01Day 58Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
51%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
- WearableSleep 6.0 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 42
- Inflammatory signalling ↑25
- BloodInflammatory load index 53
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.8 · butyrate capacity 25/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 50 ms
- Sleep
- 6.0 h
- Steps
- 3,931
- Resting HR
- 68 bpm
Daily log: GI score 55, nutritional resilience 44, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01781 | 54% | S14 | NP-02 | improved | 45 |
| P-01438 | 51% | S14 | GI-04 | improved | 56 |
| P-01556 | 51% | S14 | GI-04 | improved | 44 |
| P-01617 | 51% | S14 | SC-12 | improved | 50 |
| P-01842 | 50% | S14 | NP-02 | improved | 55 |
| P-01356 | 49% | S14 | GI-04 | improved | 42 |
| P-01436 | 49% | S14 | GI-04 | improved | 38 |
| P-01505 | 49% | S14 | NP-02 | improved | 41 |
| P-01581 | 49% | S18 | GI-04 | improved | 51 |
| P-01831 | 49% | S15 | SC-12 | improved | 49 |
| P-01458 | 48% | S14 | GI-04 | improved | 44 |
| P-01365 | 47% | S14 | SC-12 | improved | 49 |